Xlife Sciences (XLS) Stock Overview

Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences industry. The company's project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also engages in developing mono-and bispecific anti-tumor antibodies for the treatment of life-threatening cancer diseases; researching, developing, and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and identifying biomarkers for kidney diseases. Xlife Sciences AG also focuses on functional screening of antibodies by microfluidics; and offers Neuromex, a screening tool for the early detection of neurodegenerative diseases. The company is based in Zurich, Switzerland.